Mutually Opposite Signal Modulation by Hypothalamic Heterodimerization of Ghrelin and Melanocortin-3 ReceptorsAnne Rediger, Heike Biebermann, Matthias H. Tschöp et al.|Journal of Biological Chemistry|2011Cited by 109
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi‐Long Wu, Tae Min Kim, Valentina Guarneri et al.|The Lancet Oncology|2024Cited by 98
Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendationsWenyuan Xiong, Rainer Strotmann, Sofia Friberg Hietala et al.|Cancer Chemotherapy and Pharmacology|2022Cited by 12
Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin- and melanocortin-3 receptorsAnne Rediger, Heike Biebermann, CL Piechowski et al.|Experimental and Clinical Endocrinology & Diabetes|2012Cited by 5